Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Drug Profile

Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Alternative Names: Anti-TNF therapy - Numab/Tillotts; Antibody-based inflammatory bowel disease therapeutics - Numab/Tillotts; TNF-alpha blockers - Numab/Tillotts; TNF-α inhibitor antibodies- Numab/Tillotts; Tumour necrosis factor-alpha blockers - Numab/Tillotts

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Numab
  • Developer Numab; Tillotts Pharma
  • Class Antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 09 Jun 2015 TNF-α inhibitor antibodies licensed to Tillotts Pharma worldwide for the treatment of inflammatory bowel disease
  • 09 Jun 2015 Early research in Inflammatory bowel disease in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top